JP2010143932A5 - - Google Patents

Download PDF

Info

Publication number
JP2010143932A5
JP2010143932A5 JP2010002870A JP2010002870A JP2010143932A5 JP 2010143932 A5 JP2010143932 A5 JP 2010143932A5 JP 2010002870 A JP2010002870 A JP 2010002870A JP 2010002870 A JP2010002870 A JP 2010002870A JP 2010143932 A5 JP2010143932 A5 JP 2010143932A5
Authority
JP
Japan
Prior art keywords
antibody
srage
fragment
peptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010002870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010143932A (ja
Filing date
Publication date
Priority claimed from US08/948,131 external-priority patent/US6555651B2/en
Application filed filed Critical
Publication of JP2010143932A publication Critical patent/JP2010143932A/ja
Publication of JP2010143932A5 publication Critical patent/JP2010143932A5/ja
Pending legal-status Critical Current

Links

JP2010002870A 1997-10-09 2010-01-08 Ｒａｇｅのリガンド結合部位及びその使用 Pending JP2010143932A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/948,131 US6555651B2 (en) 1997-10-09 1997-10-09 Ligand binding site of rage and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000515619A Division JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用

Publications (2)

Publication Number Publication Date
JP2010143932A JP2010143932A (ja) 2010-07-01
JP2010143932A5 true JP2010143932A5 (OSRAM) 2010-11-18

Family

ID=25487337

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000515619A Withdrawn JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用
JP2010002870A Pending JP2010143932A (ja) 1997-10-09 2010-01-08 Ｒａｇｅのリガンド結合部位及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000515619A Withdrawn JP2001519401A (ja) 1997-10-09 1998-10-09 Ｒａｇｅのリガンド結合部位及びその使用

Country Status (11)

Country Link
US (1) US6555651B2 (OSRAM)
EP (2) EP2343316A1 (OSRAM)
JP (2) JP2001519401A (OSRAM)
AT (1) ATE476192T1 (OSRAM)
AU (1) AU9795898A (OSRAM)
CY (1) CY1110884T1 (OSRAM)
DE (1) DE69841806D1 (OSRAM)
DK (1) DK1023080T3 (OSRAM)
ES (1) ES2351876T3 (OSRAM)
PT (1) PT1023080E (OSRAM)
WO (1) WO1999018987A1 (OSRAM)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081241B1 (en) * 1998-10-06 2006-07-25 The Trustees Of Columbia University In The City Of New York Extracellular rage binding protein (EN-RAGE) and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
WO2000020621A1 (en) * 1998-10-06 2000-04-13 The Trustees Of Columbia University In The City Of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
CA2382095A1 (en) * 1999-08-13 2001-02-22 The Trustees Of Columbia University In The City Of New York Methods of inhibiting binding of .beta.-sheet fibril to rage and consequences thereof
US20050170382A1 (en) * 1999-10-06 2005-08-04 The Trustees Of Columbia University In The City Of New York. RAGE-related compositions
US6908741B1 (en) * 2000-05-30 2005-06-21 Transtech Pharma, Inc. Methods to identify compounds that modulate RAGE
EP1724589A3 (en) * 2000-05-30 2007-04-25 TransTech Pharma Inc. Methods to identify compounds that modulate rage
US6613801B2 (en) 2000-05-30 2003-09-02 Transtech Pharma, Inc. Method for the synthesis of compounds of formula I and their uses thereof
US7361678B2 (en) 2002-03-05 2008-04-22 Transtech Pharma, Inc. Azole derivatives and fused bicyclic azole derivatives as therapeutic agents
US7919670B1 (en) 2000-08-14 2011-04-05 The Trustees Of Columbia University In The City Of New York Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
WO2002030889A2 (en) * 2000-10-13 2002-04-18 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
AU2002245590B2 (en) 2001-03-05 2006-06-29 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
AU2002245591B2 (en) 2001-03-05 2007-05-17 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
CN1774445A (zh) * 2002-08-16 2006-05-17 惠氏公司 用于治疗rage相关病症的组合物和方法
WO2004100890A2 (en) * 2003-05-09 2004-11-25 The Trustees Of Columbia University In The City Of New York Rage g82s-related methods and compositions for treating inflammatory disorders
US7470521B2 (en) * 2004-07-20 2008-12-30 Critical Therapeutics, Inc. RAGE protein derivatives
CA2575830A1 (en) * 2004-08-03 2006-02-16 Transtech Pharma, Inc. Rage fusion proteins and methods of use
MX2007001559A (es) * 2004-08-03 2007-04-10 Transtech Pharma Inc Proteinas de fusion de receptor para productos finales glicados avanzados y metodos de uso.
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
CA2581505A1 (en) * 2004-09-27 2006-04-06 Centocor, Inc. Srage mimetibody, compositions, methods and uses
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
EP1838339A2 (de) * 2005-01-18 2007-10-03 Abbott GmbH & Co. KG Ager-peptide und deren verwendung
US9291621B2 (en) * 2005-01-18 2016-03-22 AbbVie Deutschland GmbH & Co. KG AGER-peptides and use thereof
BRPI0608401A2 (pt) * 2005-03-17 2010-11-16 Columbia Univ New York polipeptìdeo, composição farmacêutica, ácido nucleico, vetor de expressão, célula, métodos para inibir a ligação entre diáfano e o domìnio citoplasmático de rage, para identificar um agente que inibe a ligação entre o diáfano e o domìnio citoplasmático de rage, e, uso de um agente que inibe a ligação entre diáfano e o domìnio citoplasmático de rage
EA200900786A1 (ru) * 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид в качестве лекарственного средства и способ лечения патологий, связанных с воспалительными процессами, посредством пептида
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20080207499A1 (en) * 2005-06-29 2008-08-28 Gaetano Barile Rage-related methods for treating and preventing diabetic retinopathy
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
SG171670A1 (en) * 2006-05-05 2011-06-29 Transtech Pharma Inc Rage fusion proteins, formulations, and methods of use thereof
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
ES2564634T3 (es) 2007-06-14 2016-03-28 Galactica Pharmaceuticals, Inc. Proteínas de fusión de RAGE
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
JP2010537638A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
JP5894540B2 (ja) 2010-02-18 2016-03-30 ブイティーブイ・セラピューティクス・エルエルシー フェニル−ヘテロアリール誘導体とその使用の方法
JP5999542B2 (ja) * 2010-11-18 2016-09-28 国立研究開発法人農業・食品産業技術総合研究機構 リガンド様活性を有する分子の検出方法
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
US9717710B2 (en) 2012-10-05 2017-08-01 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
KR101595630B1 (ko) * 2013-01-18 2016-02-18 성균관대학교산학협력단 Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2020076668A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
EP0802797A1 (en) 1994-02-03 1997-10-29 The Picower Institute For Medical Research Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
WO1997024446A2 (en) * 1995-12-29 1997-07-10 Chiron Corporation Gene delivery vehicle-targeting ligands
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
EP0896625B1 (en) * 1996-02-21 2004-11-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant ribonuclease proteins
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US5688653A (en) 1996-06-27 1997-11-18 The Picower Institute For Medical Research 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof

Similar Documents

Publication Publication Date Title
JP2010143932A5 (OSRAM)
JP2013523703A5 (OSRAM)
JP2014132019A5 (OSRAM)
JP2012531046A5 (OSRAM)
JP2014513951A5 (OSRAM)
SMT201500125B (it) Anticorpi umani che legano il gene di attivazione dei linfociti-3 (lag-3) e loro usi
JP2013172734A5 (OSRAM)
JP2012098988A5 (OSRAM)
DK3029066T3 (da) Antistoffer med modificerede isoelektriske punkter
CR20140169A (es) Proteinas de union al antigeno cd27l
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
JP2014518898A5 (OSRAM)
JP2015501646A5 (OSRAM)
JP2013540702A5 (OSRAM)
WO2015006728A3 (en) Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
WO2008094621A3 (en) Methods for allergen detection
WO2011056958A3 (en) Detection of traumatic brain injury
WO2012058292A3 (en) Parathyroid hormone variants and assays related to disease
JP2015516943A5 (OSRAM)
JP2011236418A5 (OSRAM)
CN301923368S (zh) 电动轿车车身（ej04 c）
CN301853019S (zh) 电动轿车车身（ej02 c）
CN301845331S (zh) 电动轿车车身（ej02 d）
CN301937634S (zh) 电动轿车车身（ej02 a）
CN301937700S (zh) 电动轿车车身（ej04 a）